OTC : CMOPF

Cosmo Pharmaceuticals N.V.

$77.1 USD

-$3.34 (-4.15%)

Volume
100
Average Volume
297
Market Capitalization
$1.32B
P/E Ratio
-298.38
Dividend Yield
3.06%
Price Target
Year High
$169.90
Year Low
$64.37
Day High
—
Day Low
—
Payout Ratio
-$8.99
Current Ratio
$7.18
Company Overview

OTC

Giovanni di Napoli

Medical - Pharmaceuticals

Healthcare

CMOPF

324

IE

USD

https://www.cosmopharma.com

353 1 817 0370

16941M108

N/A

Liquidity Metrics

0.01

7.18

6.77

2.19

-8.99

Sales & Valuation

$104.82M

11.28

2.27

-73.55

-1.00

Profitability

-$0.23

-$3.63M

-3.46%

-0.88%

-0.77%

-0.59%

P/E Metrics

-298.38

2.90

2.90

Analyst Price Target & Rating

Sell

2/5

1 Analysts

%

Poll Results

About Cosmo Pharmaceuticals N.V. (OTC:CMOPF) Stock

Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of c ... olorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was founded in 1997 and is headquartered in Dublin, Ireland.

Frequently Asked Questions

What is the current Cosmo Pharmaceuticals N.V. (CMOPF) stock price?

Cosmo Pharmaceuticals N.V.(OTC:CMOPF) stock price is $77.1 in the last trading session. During the trading session, CMOPF stock reached the peak price of $169.9 while $64.37 was the lowest point it dropped to. The percentage change in CMOPF stock occurred in the recent session was --4.15% while the dollar amount for the price change in CMOPF stock was -$3.34.

CMOPF's industry and sector of operation?

The OTC listed CMOPF is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.

Who are the executives of CMOPF?

Svetlana Sigalova | Chief Financial Officer
Federico Sommariva | Chief Legal Counsel
Luigi Longo | Chief Scientific Officer
Ngo Dinh Nhan | President of Cosmo Intelligent Medical Devices
Alessandro E. Della Cha | Non Executive Chairman

How many employees does CMOPF have?

Number of CMOPF employees currently stands at 324. CMOPF operates from Riverside 2, Dublin, DU D02 KV60, IE.

Link for CMOPF official website?

Official Website of CMOPF is: https://www.cosmopharma.com

How do I contact CMOPF?

CMOPF could be contacted at phone #353 1 817 0370 and can also be accessed through its website. CMOPF operates from Riverside 2, Dublin, DU D02 KV60, IE.

How many shares of CMOPF are traded daily?

The average number of CMOPF shares traded daily for last 3 months was 297.

What is the market cap of CMOPF currently?

The market value of CMOPF currently stands at $1.32B with its latest stock price at $77.1